Actively Recruiting
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-05-07
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
A
Albert Einstein College of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome (AD-HIIES; Job's syndrome) is caused by STAT3 mutations, and is a multi-system disorder with skeletal, vascular, and connective tissue manifestations. Understanding how STAT3 mutations cause these diverse clinical manifestations is critical to our complete understanding of bone metabolism, bronchiectasis, dental maturation, and atherosclerosis. Bi-allelic mutations in DOCK8 cause a combined immunodeficiency previously described as autosomal-recessive Hyper IgE syndrome. These individuals suffer from extensive viral infections as well as have a high incidence of malignancy and mortality. The pathogenesis of this disease and long-term natural history is being investigated. Therefore, we seek to enroll patients and families with a confirmed or suspected diagnosis of HIES syndrome for extensive phenotypic and genotypic study as well as disease management. Patients will be carefully examined by a multidisciplinary team and followed longitudinally. Through these studies we hope to better characterize the clinical presentation of STAT3-mutated HIES, DOCK8 deficiency and other causes of the hyper IgE phenotype, and to be able to identify further genetic etiologies, as well as understand the pathogenesis of HIES. We seek to enroll 300 patients and 300 relatives....
CONDITIONS
Official Title
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients referred to NIH with a diagnosis or suspicion of Hyper IgE syndrome
- Patients referred for other immune syndromes showing some characteristics of HIES
- Affected subjects must be at least 1 month old
- Unaffected subjects must be aged 2 years or older
- Unaffected subjects must be able to understand and sign informed consent
- Unaffected biological relatives of HIES patients are eligible for a separate cohort
You will not qualify if you...
- No coronary CTA for patients younger than 30 years or with contraindications to IV contrast media
- Contraindications include creatinine above 1.3 mg/dL, history of multiple myeloma, recent use of metformin, or severe allergic reaction to CT contrast agents despite premedication
- Subjects with medical, psychiatric, or social conditions that would cause undue burden or increased risk as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
J
Jean M Ulrick
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here